Antihypertensive treatments in adult autosomal dominant polycystic kidney disease: network meta-analysis of the randomized controlled trials
Open Access
- 2 December 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (40) , 42515-42529
Abstract
Background: Blood pressure (BP) control is one of the most important treatments of Autosomal dominant polycystic kidney disease (ADPKD). The comparative efficacy of antihypertensive treatments in ADPKD patients is inconclusive.Keywords
This publication has 28 references indexed in Scilit:
- Graphical Tools for Network Meta-Analysis in STATAPLOS ONE, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Use of Antihypertensive Medications and Mortality of Patients With Autosomal Dominant Polycystic Kidney Disease: A Population-Based StudyAmerican Journal of Kidney Diseases, 2011
- A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney diseaseRenal Failure, 2010
- Prospective Change in Renal Volume and Function in Children with ADPKDClinical Journal of the American Society of Nephrology, 2009
- Approaches to Testing New Treatments in Autosomal Dominant Polycystic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneysKidney International, 2003
- Do polycystins function as cation channels?Current Opinion in Nephrology and Hypertension, 2002
- Diuretics versus Angiotensin-Converting Enzyme Inhibitors in Autosomal Dominant Polycystic Kidney DiseaseAmerican Journal of Nephrology, 2001